Protein-losing enteropathy, or PLE, is not a disease but a syndrome that develops in numerous disease states of differing etiologies and often involving the lymphatic system, such as lymphangiectasia and lymphangitis in dogs. The pathophysiology of lymphatic disease is incompletely understood, and the disease is challenging to manage. Understanding of PLE mechanisms requires knowledge of lymphatic system structure and function, which are reviewed here. The mechanisms of enteric protein loss in PLE are identical in dogs and people, irrespective of the underlying cause. In people, PLE is usually associated with primary intestinal lymphangiectasia, suspected to arise from genetic susceptibility, or "idiopathic" lymphatic vascular obstruction. In dogs, PLE is most often a feature of inflammatory bowel disease (IBD), and less frequently intestinal lymphangiectasia, although it is not proven which process is the true driving defect. In cats, PLE is relatively rare. Review of the veterinary literature reveals that PLE was lifeending in 54.2% of dogs compared to published disease-associated deaths in IBD of <20%, implying that PLE is not merely a continuum of IBD spectrum pathophysiology. In people, diet is the cornerstone of management, whereas dogs are often treated with immunosuppression for causes of PLE including lymphangiectasia, lymphangitis, and crypt disease. Currently, however, there is no scientific, extrapolated, or evidence-based support for an autoimmune or immune-mediated mechanism. Moreover, people with PLE have disease-associated loss of immune function, including lymphopenia, severe CD4+ T-cell depletion, and negative vaccinal titers. Comparison of PLE in people and dogs is undertaken here, and theories in treatment of PLE are presented.
| COMPARATIVE PATHOPHYSIOLOGY OF PROTEIN-LOSING ENTEROPATHY
In dogs and people, protein-losing enteropathy (PLE) is associated with numerous related or unrelated diseases (Table 1) , but there are a limited number of mechanisms by which plasma protein is lost through the gastrointestinal (GI) tract [1] [2] [3] :
• Physical or functional lymphatic obstruction leading to "overflow" lymph leak, for example, congenital or acquired lymphatic disease.
• Release of cellular mediators affecting vascular permeability and causing fluid egress into tissues, for example, widespread mast cell activation, eosinophilic gastroenteropathy.
Abbreviations: APCs, antigen presenting cells; ATIII, antithrombin III; BECs, blood endothelial cells; CCECAI, canine chronic enteropathy clinical activity index; CD, Crohn's disease; CE, chronic enteropathy; CIBDAI, canine IBD activity index; CRP, C-reactive protein; CT/MRI, computerized tomography/magnetic resonance imaging; EFA, essential fatty acid; α1 PI, alpha 1 protease inhibitor; FISH, fluorescence in situ hybridization; GALT, gut-associated lymphoid tissue; GI, gastrointestinal; GL, granulomatous lymphangitis; HS, heparan sulfate; IBD, inflammatory bowel disease; IL, intestinal lymphangiectasia; IMPDH, inosine monophosphate dehydrogenase; IP, immunophenotyping; LCFA, long-chain fatty acids; LECs, lymphatic endothelial cells; LN, lymph node; MCFA, medium-chain fatty acids; MCT, medium-chain triglycerides; PARR/PCR, PCR for antigen-receptor rearrangements; PIL, primary intestinal lymphangiectasia; PLE, protein-losing enteropathy; PLN, protein-losing nephropathy; RER, resting energy requirement; PTE, pulmonary thromboembolism; SCFA, short-chain fatty acids; SCWT, Soft Coated Wheaten Terrier; SI, small intestinal; TE, thromboembolism; UC, ulcerative colitis; UFH, unfractionated heparin sulfate; YT, Yorkshire Terrier; YT-PLE, Yorkshire Terrier protein-losing enteropathy.
• Mucosal inflammation (nonerosive or erosive/ulcerative), for example, inflammatory bowel disease (IBD).
In each mechanism, protein-rich fluid accumulates in the interstitium and passes into the GI tract via mucosal tight junctions, without requiring mucosal epithelial disruption or ulceration ( Figure 1 ). 3, 4 Albumin is the most affected protein in people because of its slow turnover rate, which is why protein loss in PLE is diagnosed by detection of hypoalbuminemia. 5 As a water-soluble protein in dogs and people, albumin maintains plasma oncotic pressure and transports hormones, fatty acids, ions, and bilirubin. In health, enteric losses in people occur as sloughed enterocytes and normal secretions, and account for around only 1-2% of the entire protein pool and less than 10% of total albumin. 6 In steady state, albumin broken down approximates albumin synthesized in people, but in PLE, protein wasting can amount to 60%
of the total protein pool. 7, 8 The most severely diminished are long half-life proteins with limited ability to respond rapidly-albumin, immunoglobulins, and ceruloplasmin. 5 Hepatic synthesis in PLE is normally accelerated so that proteins with shorter half-lives such as IgE, clotting factors, prealbumin, and transferrin are preserved near normal. 1, 5 Protein-losing enteropathy can be asymptomatic but can also present as a life-threatening condition with effusions, lymphedema, and in people, severe disfigurement. Immune defenses are disrupted because of loss of lymphocytes, globulins, iron, calcium, and other serum components (lipids, fat soluble vitamins). 2, 4, 5, 7, 8 The immunological deficits documented in PLE are numerous in people, including impaired antibody function, B-cell depletion, diminished IgG, IgA, and IgM, and T-cell depletion, especially CD4 + T cells. 2 Despite profoundly low CD4 + counts, opportunistic infection appears to be uncommon in people. 9, 10 Similar studies are lacking in dogs, but depletion in these key components is to be similarly expected.
Sudden death caused by thromboembolism (TE) occurs in PLE and
can manifest in dogs that have clinically "silent" disease. 11 The mechanism is not well defined, but suggested causes of PLE-associated thrombosis include systemic inflammation, altered vitamin K absorption, loss of antithrombin III (ATIII), hyperaggregation of platelets, hyperfibrinogenemia, and vascular compromise.
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| LYMPHATIC STRUCTURE AND FUNCTION
The lymphatics are a unidirectional vascular network forming an extensive drainage system throughout the body with roles of extracellular fluid homeostasis, fat absorption and transport, and immune system function. 3 Running parallel with the venous system, the lymphatic system is broadly divided into lymphatic capillaries (where interstitial fluid enters), prenodal and postnodal vessels, and collecting vessels. 3 Collecting vessels drain to the thoracic duct via discrete regional lymph nodes (LNs) before joining the confluences of large veins. 3, 10 Specialized lymphatic endothelial cells (LECs), with structural similarity to blood endothelial cells (BECs), form lymphatic capillary walls. Endothelial Growth Factor 3.
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| Lymphatic capillaries
The LECs of capillary walls are not tightly joined, but only the cell edges overlap, forming "flap-like" valves ( Figure 1 ). 19 Lymphatic endothelial cells have no support (mural) cells but attach to the extracellular matrix via fine collagen filaments that anchor to surrounding tissues. This allows LECs to operate like swinging doors, receiving interstitial fluid in a strictly 1-way system. 3 When pressure in the lymphatic capillary exceeds interstitial pressure, the endothelial "door" flap remains shut, preventing lymph from leaving. 3, 20 But when interstitial pressure exceeds lymphatic capillary pressure, the "doors" flap open and interstitial fluid moves to the lymph system. 20 Not only fluid but also other substances such as proteins and pathogens, inflammatory and neoplastic cells can join lymph in this manner. 21, 22 Interstitial proteins enter lymph capillaries easily, despite being too large to enter blood capillaries. 22 
| Collecting lymphatics and lymphangions
Lymphatic capillaries merge and drain into precollecting vessels. The spindle-shaped LECs of precollectors are continuously adherent, with "zipper"-like junctions. 23 Intraluminal valves prevent backflow of lymph, and smooth muscle cells enable intrinsic contractility. 20, 21, 24 Precollectors merge into larger collecting vessels, made up of a series of subunits called "lymphangions" (the section between 2 intraluminal valves). 24, 25 The collecting vessel wall is organized into a layer of continuously adherent LECs (intima), a basement membrane comprising laminin and type IV collagen, and circumferential smooth muscle (media). 
| Intestinal lymphatic networks
The microanatomy of the intestinal lymphatics is described in ultrastructural studies, and in dogs and people there are 3 layers: central villus lymphatics (lacteals), submucosal lymphatics, and smooth muscle lymphatics. 19, 27 The lacteals connect to the submucosal lymphatic network with abundant interconnections. Injection of tracers shows free flow of fluid throughout the submucosal network and into adjacent villi, suggesting a valveless system lacking in smooth muscle and spontaneous contraction. 20 The lymphatic vessels draining the muscle wall form a separate and noncommunicating network. Both networks transport lymph to collecting lymphatics 24 with 1-way valves and spontaneous contractions propelling lymph away from the intestine to the mesentery. Diagrammatic representation of "PLE syndrome" diseases in dogs (lymphangiectasia, lymphangitis, crypt lesions, IBD, mucosal ulceration) and the effect of Starling's forces on intestinal osmolality and the interstitial-lumenal oncotic gradient. Protein leaks into the small intestine passively, via an oncotic gradient from the interstitium to the lumen. If osmotic pressures equilibrate, a reduction in passive leak is expected. When the intestinal lumen has a higher oncotic pressure than the interstitium, such as postprandially, the gradient may be reversed, depending on the underlying pathology. The drainage function of lymphatic vessels is crucial for resolving inflammatory reactions in the interstitium, and during inflammation, lymphatics can proliferate through lymphangiogenesis to remove debris directly or via phagocytic cells. 3, 17, 21 Development and proliferation of lymphatic vessels is primarily mediated by vascular endothelial growth factor C in pathological states. 29 
| Lymph nodes
The LNs, spleen, and other secondary lymphoid organs (eg, intestinal
Peyer's patches) are anatomically located to capture foreign antigen and antigen presenting cells (APCs) for immune surveillance. 
| Immune surveillance
Lymphatic vessels function in immune surveillance as the major conduit of antigens and immune cells from the periphery, through the tissues of the immune system. The highly organized microarchitecture of LNs hosts peripheral APCs to meet and inform naive T cells. 25, 32 The largest immunologic organ is the GI tract, where immunologic barrier function plays a vital role in maintaining homeostasis. The gutassociated lymphoid tissue (GALT) consists of the intestinal lamina propria cells, intraepithelial lymphocytes, Peyer's patches, and mesenteric LNs. 33 Lymphocytes continuously recirculate from the bloodstream into intestinal lymph through GALT, to exert immune control in almost all tissues. 34 Mature lymphocytes migrate from blood to tissues, and back to the bloodstream via lymph, once or twice a day, until the cell either finds its antigen or is removed by apoptosis. 35 
| Intestinal lymphatics
Dietary fat is absorbed into lacteals ( Figure 1 ) and transported as chyle to the bloodstream. Resin casts of canine small intestinal (SI) lymphatics have been produced using methacrylate resin and imaging by scanning electron microscopy. 19 The casts show the lymphatic canal of the jejunum as a single, blind-ending, central tubule, with circular constrictions at the villus tip, and oval indentations corresponding to impressions by endothelial nuclei (Figure 2 The immunohistochemical markers Prox-1 and CD31 separate lymphatic from blood capillary endothelium. 75 In the SCWT, lymphatic dilatation (17% prevalence) is reported to be strongly associated with lymphangitis (35% prevalence), and less so with IBD, whereas the presence of all 3 lesions concurrently was rare. The obvious place to seek an anomaly is in the lymphatic endothelium or in the fine collagen fibers that anchor lymphatic capillaries to surrounding connective tissue, but none has ever been described.
| Granulomatous lymphangitis
Lymphangitis and granuloma formation are rare in dogs with PLE.
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Clinical presentation is typical for PLE but can also include fever and abdominal pain. 51 The histological description is of transmural intestinal granulomas containing large "multinucleate giant cells," neutrophils, Cumulative histology scores from 3 canine studies of PLE, per the WSAVA GI standardization group scoring system. 48, 53, 65 GI, gastrointestinal; PLE, protein-losing enteropathy. Numbers on bars are the number of dogs D i e t a r y c h a n g e P a r e n t e r a l n u t r i t i o n Breed frequency across studies 56 The lesions are described as dilated cystic crypts containing sloughed epithelial cells, debris, and leucocytes 67 and are often called "abscess" by pathologists but are not known to be associated with a specific pathogen (Figures 1 and 8) . Their histological appearance, packed with proteinaceous and cellular debris, seems inconsistent, however, with simple cystic malformation. Parallels drawn with parvovirus infection, that is, villus collapse and fusion and crypt distension, led researchers to undertake intestinal immunostaining for parvovirus antigen in 2 dogs, which was negative. 67 In people, crypt lesions are reported to be highly predictive of ulcerative colitis (UC). 83 Increased numbers of neutrophils and mucosaassociated bacteria are found to colonize crypts in UC, suggesting an opportunist role for bacteria in "cryptitis" or crypt "abscess" formation. 83, 84 Investigation for a similar etiology in YT crypt PLE (YT-PLE) • Bodyweight (11 to 20 kg P = 0.041).
• Mildly increased serum CRP concentration (P = 0.004).
• Normal serum levels of calprotectin (P = 0.031) and calgranulin (S100A12, P = 0.047).
• Serum alpha1-PI concentrations were lower in dogs with PLE (P < 0.001) vs food responsive disease (FRD).
• Serum CRP (P < 0.001) was higher in dogs with PLE (median, 13.0 mg/L) vs FRD (median, 1.4 mg/L).
• Moderate correlation (r = 0.659; P < 0.01) between CIBDAI and CCECAI scores. • Dogs with albumin >14.3 g/L had a shorter duration of primary treatment than dogs with albumin <13.0 g/L (P = 0.040).
• Longer duration of primary treatment was associated with: 1. Bodyweight (from 9.6 to 24.7 kg, P = 0.04). 2. Ascites presence (P = 0.013). 3. Mild lacteal dilation presence (P = 0.028).
Duration of primary treatment was shorter with chlorambucil-prednisolone treatment than azathioprine-prednisolone (P = 0.004).
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• Responders based on normalization of CIBDAI (P < 0.0002), or CCECAI (P = 0.0004), and albumin (P < 0.04) showed longer survival time than nonresponders.
• Variables associated with shortened survival time were: 1. Higher CIBDAI score (P < 0.0003). 2. Increased serum BUN (P < 0.03).
• Authors include in their analysis of PLE, dogs with small-cell (19) and large cell lymphoma (10); survival data for small cell lymphoma was comparable with non-neoplastic causes of PLE.
• Normalization of CIBDAI and plasma albumin concentration within 50 days of initial treatment was associated with a longer survival time. 
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• Increased serum BUN in short-term survivors (STs, P < 0.05).
• Bodyweight was higher in STs (P < 0.05).
• Serum albumin, total protein and cholesterol were lower in STs (P < 0.01).
• A CCECAI score of > 5 at 1 month after diagnosis was the best predictor for poor outcome. • Percentage of dogs receiving immunosuppressive drugs between outcome groups was different, with negative outcome dogs receiving more immunosuppressive drugs (p < 0.001).
• A greater number of dogs treated with diet alone were in the good (versus negative) outcome group (13/22 vs 2/21, p < 0.001).
• CCECAI scores between good versus negative outcome groups were not different.
has been undertaken. 81 In this work, involving 12 YT (median age 
| Lymphoplasmacytic enteritis
In dogs, IBD is currently thought to arise from immune system dysfunction, adverse reaction to dietary components, intestinal bacteria (dysbiosis), and genetic susceptibility. 86, 87 In PLE, IBD ("IBD-PLE") causes protein loss either via leaky intercellular junctions or severe mucosal exudation (Figure 1 ). Although inflammatory processes can alone increase protein turnover, this would not usually cause hypoproteinemia unless very severe and extensive. Secondary IL can accompany IBD, although defining primary versus secondary IL is problematic. 46, 47 Now that antibodies to lymphatics are available, it might become possible to better define primary lymphatic disease versus IBD as the driving force in IBD-PLE.
There are numerous published accounts of IBD-PLE in dogs that describe the absence of lymphatic disease. 11, 77, 88 It is unclear whether lymphatic changes are interlinked with IBD severity; however, the idea that IBD-PLE could lack a lymphatic response deserves careful consideration when structural studies have confirmed that every villus contains a thin-walled lymphatic capillary connected to a valveless vascular network (Figures 1 and 2) . The bowel is a huge organ, and in most cases the ileum and majority of the jejunum are never sampled, More recently it was found that a high CRP concentration is a negative prognostic indicator in PLE (P = .004), 65 but in other work, there was no difference between responders and nonresponders. 55 There is no clear consensus on the diagnostic utility of CRP, and as a nonspecific inflammatory marker, its validity across studies may depend on factors such as geographical region (endemic disease, parasitism, animal welfare standards), and laboratory methodology. More recently, fecal α1 PI, a measurable serum protease inhibitor lost into the bowel in PLE, was reported to distinguish dogs with moderate to severe intestinal crypt disease and lacteal dilatation (n = 54) from those without (n = 66) with sensitivity of 44%-74% and specificity of 57%-93%. 100 Being a noninvasive surveillance tool for screening PLE-susceptible breeds, α 1 PI is also helpful to detect PLE in animals with concurrent PLN or hepatic insufficiency.
| DIAGNOSIS OF PLE
Fecal calgranulin-C (S100A12) is a noninvasive marker of IBD in people. 101, 102 A calcium-binding protein, S100A12, is secreted by activated neutrophils, a cell type abundant in the intestinal mucosa of IBD in people. When tested and validated for accuracy in distinguishing dogs with IBD from healthy controls, fecal S100A12 showed a sensitivity of 65% and specificity of 84%, with a misclassification rate of 20%. 100 In another study, serum S100A12 did not identify dogs with PLE; however, reference range serum S100A12 and serum calprotectin concentrations (P = .04 and P = .03, respectively), were found to be negative prognostic indicators in dogs with PLE. In people, calprotectin is another useful IBD marker, 103 corresponding to a neutrophil cytosol protein with resistance to bacterial degradation. In dogs, serum calprotectin ≥296 μg/L showed sensitivity of 82.4% and specificity 68.4% for IBD detection, although it did not correlate with CIB-DAI, CRP, or histology. [104] [105] [106] The "gold standard" biomarkers for IBD and PLE in dogs have yet to be realized. The dissimilarities in histological appearance of human and canine diseases, for example, neutrophilic/granulomatous inflammation (people) versus lymphoplasmacytic inflammation (dogs and cats), and transmural (people) versus mucosal (dogs and cats) distribution, imply probable species specificity in a high performing biomarker. Furthermore, the interconnected structure of the "web-like" and valveless intestinal network implies that IL would not usually be confined to submucosal lymphatics without some degree of transference of lymph capillary hypertension to the lacteal. Diagnostic accuracy of endoscopic biopsy inevitably depends on sample quality 88 and 6 (high quality) to 15 (moderate quality) duodenal samples are advised in dogs, except for diagnosis of crypt lesions, which reportedly requires 13-20 biopsies. The sensitivity of endoscopy for lymphoma diagnosis was >90%, regardless of biopsy quality. 88 The gross appearance of the duodenal mucosa and particularly the presence of white villus tips are inadequate to accurately predict IL, with reported sensitivity of 68% and specificity of 42% for endoscopic appearance alone in IL diagnosis. 96 The endoscopic appearance of PIL in people reveals obvious, creamy yellow villi corresponding to marked dilatation of intestinal lymphatics. 40 Histology confirms the presence of dilated mucosal and submucosal lymphatics, from a few millimeters to centimeters. Lacteals can be dilated in many villi or only a few. Mucosal abnormalities vary, but the absence of villous atrophy, significant mucosal/submucosal defect, and microorganisms, is key to diagnosis. Endoscopy can be negative when intestinal lesions are segmental or localized. In these cases, video capsule endoscopy or enteroscopy can be diagnostic. 40 Ultrasonography can show dilatation of intestinal loops, wall thickening, severe mesenteric edema, and ascites. 109 Contrast computerized tomography (CT) identifies localized IL, showing typically diffuse, nodular, small bowel thickening with or without dilatation, and a "halo sign" due to bowel swelling and edema. 42, 110 Magnetic resonance imaging has been successfully applied in people with IL to evaluate for localized and systemic disease. 111 The use of CT and MRI for the purpose of PLE diagnosis in dogs is not reported. 
| Intestinal biopsy in PLE
| Mucosal biopsy immunophenotyping and polymerase chain reaction for antigen-receptor rearrangements
When routine histology fails to differentiate a benign, polyclonal lymphoid proliferation from a monoclonal, neoplastic process, clarification may be achieved using immunophenotyping (IP) for lymphocyte markers 118 or polymerase chain reaction (PCR) to detect clonal B and T cell populations (PCR for antigen-receptor rearrangements). 118 Both methods utilize the paraffin wax-embedded histology block, without need for further sampling. The consensus of the WSAVA International GI Standardization Group is that IP retains precedence over clonality testing as a diagnostic procedure. 72 
| MANAGEMENT OF PLE
In treating PLE, defining the precise nature of protein loss, that is, inflammatory, exudative, or structural (lymphatic or crypt distension) determines the selection of appropriate therapeutics. To optimize recovery rates, an otherwise safe assumption is that the processes of lymph fluid loss, active protein exudation, and leaky cell junctions could be present at some juncture in every affected bowel.
| Diet
A low-fat diet with supplementary MCT is the cornerstone of PLE management in people, proven to be the most effective, most widely prescribed approach and with minimal adverse effects. 40, 119 Desai et al. showed that within a few weeks, a high-protein, low-fat diet with MCT not only improves clinical signs but also reduces mortality in people. 37 The need for dietary control in people appears to be permanent, because clinical and biochemical findings reappear after lowfat diet withdrawal. 40 Dietary fat restriction prevents engorgement of intestinal lymphatics with chyle, preventing rupture of grossly distended lacteals. Medium-chain triglycerides are directly absorbed into the portal venous circulation and provide nutrient fat without lacteal engorgement. 40 The benefit of MCT should not be assumed to be restricted to lymphatic bypass. Medium-chain triglyceride digestion is rapid and simple, without stimulating cholecystokinin secretion or utilizing the actions of bile and lipase for absorption. Absorption of MCT occurs via passive diffusion along the GI tract into the portal system bound to albumin. No further packaging or modification of MCT molecules is required. Moreover, MCTs are not dependent on the carnitine acyltransferase system for transport into the mitochondria for β-oxidation. This provides the ability for more rapid metabolism of MCTs and improved utilization even in states of protein deficiency.
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Suggested dietary proportions for dogs with PLE are calories from carbohydrate 55-60%, total fat calories 10-15%, and protein calories 25-30%, using a highly digestible protein (>87%). 36 The canine diet must always contain LCFAs for provision of EFAs, and supplementation of fat-soluble vitamins (A, D, E, K) is particularly important when dietary fat content is low. Available low-fat commercial diets are listed in Table 4 ; however, the choice of diet in PLE cases is often dictated by patient appetite and preference. Many (especially YT) are historically fussy eaters (perhaps reflecting more chronic subclinical GI disease), and are frequently anorexic. Nutritional management in PLE is paramount and if not effectively implemented, the cycle of protein leak and catabolism will continue until eventually death is inevitable.
In selective eaters or those with unreliable appetite, the authors routinely place an esophagostomy tube (E-tube) during the endoscopy anesthesia. This step seems to be the key to success in PLE management for both patient (particularly YT) and owner. Often very unwell and with critically low serum proteins, these patients need every modicum of support. The pet-owner bond can be disrupted when owners force their pet to take medications and a specific diet, and life can become unbearably stressful and anxious for both. The authors' experience is that in retrospect, the feeding tube was not infrequently a life-saving measure. When tube feeding is initiated, a commercial low fat, blenderized canned food is supplemented up to 30% protein calories (with whey or pea protein powder) and divided into 6-8 meals To supplement caloric density, MCT can be given in the form of mixed C8 and C10 triglycerides to provide up to 30% of total fat calories (better achieved via an E-tube, due to variable palatability; higher levels can be ketogenic).
A measurable response should be apparent promptly if nutritional intake is appropriate in content and proportion. In severely hypoalbuminemic dogs in particular (albumin <1.5 g/dL), if serum albumin has not begun to increase after 3 days, the protein proportion can be increased to 35%, aiming to achieve positive protein balance. If there is no increase after 5-7 days, the authors switch to a different protein source, in case it should (on case-by-case basis) be more easily digested and absorbed, and better (immunogenically) tolerated. In some cases (author observation), animals achieve normalization of serum albumin Immune suppression is often suggested to be reserved as "last resort" treatment, for IBD 87 and some animals with moderate to severe change are reported to clinically respond completely to dietary management alone. 71, 87, 125 The clinical severity of IBD does not always correlate with the histological severity score, 72 and neither variable is demonstrated to predict the requirement for immune suppressive treatment. 71, 73 Commonly used immune suppressive medications in dogs are prednisolone, cyclosporine, azathioprine, chlorambucil, and mycophenolate. In a small study, improved survival of dogs with PLE was associated with the use of prednisolone plus chlorambucil (10/14 alive) versus prednisolone plus azathioprine (2/13 alive, P = .004).
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Consideration of the type of inflammation present and agent pharmacodynamics should help to guide drug choice. Mycophenolate, chlorambucil, and azathioprine can all cause severe GI toxicosis and myelosuppression.
Azathioprine is a purine antimetabolite that inhibits nucleic acid synthesis causing chromosomal breaks and disruption of cellular metabolism. Azathioprine is poorly absorbed PO and clinical response can take up to 6 weeks. 126, 127 Chlorambucil is a cytotoxic alkylating agent with delay of up to 4 weeks before clinical response is appreciated. 126, 127 It is well absorbed PO and highly bound to plasma proteins, which is of note when used in hypoproteinemic animals. Cyclosporine suppresses cell-mediated immunity and might be more efficacious in suppressing T-cell-macrophage interactions in granulomatous inflammation. 127, 128 However, it is variably absorbed PO and can be less well absorbed in the diseased bowel. 129 Mycophenolate mofetil, a prodrug of mycophenolic acid, is an inhibitor of inosine monophosphate dehydrogenase (IMPDH), a rate-limiting enzyme in nucleotide synthesis. 130 Lymphocytes are particularly dependent on IMPDH, unlike other cell types (eg, neutrophils) that recycle nucleotides via a salvage pathway.
Mycophenolate mofetil is thought to suppress proliferation specifically of lymphocytes 130 and has many desirable properties in treating IBD: absorbed PO, "neutrophil-sparing," and without extensive time delay. 127 However, it causes significant GI irritation, and in people has a "black box" warning (serious or life-threatening risk) for lymphoma. 126 Regarding corticosteroids, budesonide is a preparation with topical activity in the GI tract but has not been specifically evaluated for PLE treatment. 127 Some practitioners use parenteral dexamethasone due to concerns that prednisolone is insufficiently PO absorbed, but in studies of people with Crohn's disease, this theory is not well supported. deficiency of HS has been discovered in the basolateral surface of the enterocyte. 134 Exogenous heparin treatment to these children reversed enteric protein loss at doses that are considered subtherapeutic for anticoagulation in people (5000 U/day SC). 135 The precise mechanism by which HS relieves protein loss across the mucosa is unknown, but the effect has been reported in several other PLE-associated diseases. [135] [136] [137] The ability of HS treatment to reverse PLE in dogs is hopeful but has not yet been evaluated (see antithrombotics).
| Octreotide
Octreotide is a long-acting somatostatin analogue that suppresses GI motility and hormone secretion in the pituitary gland, pancreas, and intestine. In 1998, the efficacy of octreotide in 1 human PIL patient was first reported, and it has since, as monotherapy with MCT diet, been shown to lead to long-term clinical, biochemical, and histological remission of PLE of differing etiologies in people. 138 The mechanism of action of octreotide in diminishing protein loss through the GI tract is unclear. Somatostatin receptors exist in normal gut lymphoid tissue and on veins and venules. 139 Both somatostatin and octreotide normally decrease splanchnic blood flow via vasoconstriction and also decrease intestinal motility, gastric emptying, gallbladder contraction, pancreatic secretion, and triglyceride absorption. 140, 141 Theorized mechanisms of octreotide's action in PIL include decreased intestinal fat absorption, inhibition of GI vasoactive peptides, and stimulation of the autonomic nervous system. 138 Octreotide is expensive and administered parenterally, and in responsive patients discontinuation usually causes PLE recurrence. 142 Reported adverse effects in human clinical trials were diarrhea, abdominal pain, nausea, headache, cholelithiasis, hyperglycemia, and constipation. 40, 119, 140, 143 Octreotide has been used in dogs for the treatment of insulinoma. 144 
| Antithrombotics
The published data described here suggests that TE occurs in around 6% of PLE cases but is almost certainly underestimated, being a "silent" killer. 13, 145, 146 Prophylaxis with antithrombotic medication could prevent death and is usually well tolerated, inexpensive, and with minimal adverse effect. There is no consensus on optimal antithrombotic treatment in PLE, and options include unfractionated heparin sulfate (UFH), low-molecular-weight heparin, clopidogrel, and lowdose aspirin. In consideration of the markedly beneficial effect on PLE in people, UFH would be a logical choice but is poorly tolerated by painful SQ injection q8h. For years, UFH was thought to be minimally absorbed PO, supported by minimal changes in plasma APTT levels after oral administration, but sublingual and oral UFH absorption has since been demonstrated in numerous species including dogs. [147] [148] [149] There is now published evidence of reliable oral UFH absorption in healthy dogs, evidenced by ATIII inhibition and anti-Xa activity. 150 Recovery of UFH from both plasma and urine in people and dogs also supports that UFH administered PO is absorbed and widely distributed. 148, 150 In dogs, no negative effects were observed to indicate UFH-induced hemorrhage, excessive ATIII consumption, or thrombocytopenia during oral heparin administration. 150 Further studies determining optimal oral dosage in dogs, and clinical benefit in disease states has not yet emerged. Clopidogrel and low-dose aspirin are frequently used as antiplatelet agents in dogs with PLE, either alone or in combination. 145 The optimal combination, dosages, and required duration of treatment is unknown; however, dogs in complete clinical remission of PLE can die suddenly from TE, 145 which suggests a benefit of prolonged treatment.
| Other
Other medications used empirically to treat IBD and PLE are antimicrobials (metronidazole, tylosin, doxycycline), gut protectants (acid reducers, sucralfate), antiemetics, and probiotics. 11, 36 The use of gut protectants might help to maintain a lumenal environment that favors ongoing repair of the mucosal barrier. If mucosal ulceration or neutrophilic inflammation are present, broad spectrum antimicrobial treatment might be warranted, for example, doxycycline, amoxycillin-clavulanate, cephalexin, and FISH analysis alongside culture data would also serve to guide antimicrobial treatment. Cobalamin deficiency has been associated with a negative prognosis, 93 and supplementation by oral and parenteral routes is described. 151 Although rare, folate deficiency can be corrected by oral supplementation. Corrections of deficits in calcium and magnesium in PLE have been described by Kimmel et al., 61 by administration of "constant rate infusions of magnesium sulfate Without this 1-way system, the external compressive "pumps" could merely contribute to lymph entering interstitial tissues and the bowel lumen, so that an unrelenting cycle of lymph leakage, local irritation, protein loss, and edema formation develops. Anterograde lymph flow then becomes largely dependent on passive (Starling) forces. A steady state could be reached by catabolism of interstitial tissue proteins or lymphangiogenesis to restore lymph drainage, until these compensatory mechanisms are also exhausted. 158 Animals that present with panhypoproteinemia and effusions are frequently in a late stage of a dangerous "PLE cycle" disease.
It follows that diminishing the protein leak might be achieved by
(1) emphasis on Starling forces (2) by modifying intestinal peristalsis, and (3) bypass of the affected intestinal area, if PLE is confirmed to be segmental.
| Emphasis on Starling forces
Osmolality of the human duodenum in fasted state is 200-250 mOsm/kg, versus serum osmolality, 290-300 mOsm/kg. 159 In healthy people, the SI environment changes on a time-after-food basis. The effect of different "fed states" on SI intraluminal osmolality was evaluated by administering the nutritional drink Ensure Plus. 159 Fasted state osmolality values were in general hypo-osmotic, with overall median value of 224 mOsm/kg, whereas hyperosmotic values (as high as 600 mOsm/kg, median 285 mOsm/kg) were found in fed states during the first 3 hours of digestion. 159 In dogs, fasted intestinal lumen osmolality is around 200-250 mOsm/kg and serum osmolality 290-310 mOsm/kg. ance is reached. 42 The optimal level of protein supplementation in dogs with PLE has never been determined. A warmed, liquid consistency, low-fat diet appears logically advantageous over dried or dense wet food to reduce GI "work" and to optimize enterocyte contact and surface tension for maximal nutrient absorption.
| Modifying intestinal peristalsis
Intestinal peristalsis passively facilitates lymph transport and a hypomotile bowel can develop lymph stasis. Studies of GI motility in PLE are lacking; however, bowel swelling and edema might alter GI transit times. Motility can be assessed radiographically using barium impregnated polyethylene spheres, barium fluoroscopy, radionuclide transit, or video capsule endoscopy. When dysmotility is present, prokinetic treatment, for example, metoclopramide (0.2-0.5 mg/kg PO q8h) or cisapride (0.1-0.5 mg/kg PO q8h), should be considered, with careful monitoring for signs of worsening hypoproteinemia or deteriorating clinical condition. Enhanced bowel contractility could also serve to accelerate protein and lymph loss and is likely to be more safely initiated alongside a well implemented feeding plan.
| Bypass of segmental PLE
Enterectomy for localized areas of lymphangiectasia has been curative in people with segmental PLE. 161 The reasons for disease localization to a particular anatomical area are unknown, but improvement can be only transient because of disease recurrence. Segmental PLE has been diagnosed using (99 m) Tc-labeled albumin scintigraphy. 162, 163 Segmental presentations in dogs and breed-specific anatomical localization are not recognized so far but are unexplored phenomena. Serial monitoring using scintigraphy (with radiolabeled canine albumin) could help to identify dogs with lesion localization that might be safely amenable to surgical treatment.
| CONCLUSIONS
In dogs, PLE is most frequently associated with lymphangiectasia and IBD and is managed empirically with immune suppressive agents, most frequently prednisolone, azathioprine, cyclosporine, and chlorambucil, as well as dietary change and antimicrobials. The use of immunosuppressive agents remains controversial in any of these disorders and is not utilized in people for the treatment of most types of PLE. Lifelong dietary management is the cornerstone of treatment, and recent studies in dogs support this approach. 53, 64 Current treatment is associated with >50% fatality, which logically drives management toward the safest approach until pathophysiology is better understood and specific, nonempirical treatment can be formulated.
The investigative history of E. coli-associated granulomatous colitis in the Boxer dog (GC) highlights exceptionally well that the rationale for exerting immune suppression, albeit as a "last resort" treatment, invites careful consideration. Historically, for around a half century, GC was often treated with immune suppression and with usually fatal outcome. When clinical observations with antimicrobials drove the discovery of an infectious etiology, GC became largely curable. 164, 165 An excellent relationship with the internist and a high level of owner support are also a crucial aspect of managing PLE.
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